146 related articles for article (PubMed ID: 11309641)
21. XbaI polymorphism of the estrogen receptor alpha gene influences the effect of raloxifene on the endothelial function.
Zavratnik A; Zegura B; Marc J; Prezelj J; Pfeifer M
Maturitas; 2010 Sep; 67(1):84-90. PubMed ID: 20609538
[TBL] [Abstract][Full Text] [Related]
22. [Raloxifene: a selective modulator of estrogen receptors].
van den Brûle FA; Kalbus MF; Gaspard UJ
J Gynecol Obstet Biol Reprod (Paris); 1999 Dec; 28(8):788-99. PubMed ID: 10635481
[TBL] [Abstract][Full Text] [Related]
23. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature.
Cosman F; Baz-Hecht M; Cushman M; Vardy MD; Cruz JD; Nieves JW; Zion M; Lindsay R
Thromb Res; 2005; 116(1):1-13. PubMed ID: 15850603
[TBL] [Abstract][Full Text] [Related]
24. Are the serum levels of sCD40L modified by raloxifene in postmenopausal women?
Oviedo PJ; Hermenegildo C; Novella S; Tarín JJ; Cano A
Eur J Obstet Gynecol Reprod Biol; 2008 Oct; 140(2):296-7. PubMed ID: 18583017
[No Abstract] [Full Text] [Related]
25. The science of selective estrogen receptor modulators: concept to clinical practice.
Jordan VC
Clin Cancer Res; 2006 Sep; 12(17):5010-3. PubMed ID: 16951214
[No Abstract] [Full Text] [Related]
26. Raloxifene: another selective estrogen modulator.
Kellen JA
In Vivo; 2001; 15(6):459-60. PubMed ID: 11887329
[TBL] [Abstract][Full Text] [Related]
27. [Estrogens and selective estrogen receptor modulators in the treatment of osteoporosis].
Ribot C; Tremollieres F; Pouilles JM
Ann Med Interne (Paris); 2000 Oct; 151(6):490-6. PubMed ID: 11104929
[TBL] [Abstract][Full Text] [Related]
28. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.
Lee WL; Cheng MH; Chao HT; Wang PH
Taiwan J Obstet Gynecol; 2008 Mar; 47(1):24-31. PubMed ID: 18400579
[TBL] [Abstract][Full Text] [Related]
29. Effect of raloxifene on sexual function in postmenopausal women.
Kessel B; Nachtigall L; Plouffe L; Siddhanti S; Rosen A; Parsons A
Climacteric; 2003 Sep; 6(3):248-56. PubMed ID: 14567773
[TBL] [Abstract][Full Text] [Related]
30. Coronary heart disease in women.
Anderson PW; Moscarelli E
N Engl J Med; 2000 Dec; 343(25):1892; author reply 1892-4. PubMed ID: 11117987
[No Abstract] [Full Text] [Related]
31. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
Dias AR; Melo RN; Gebara OC; D'Amico EA; Nussbacher A; Halbe HW; Pinotti JA
Climacteric; 2005 Mar; 8(1):63-70. PubMed ID: 15804733
[TBL] [Abstract][Full Text] [Related]
32. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.
Jordan VC
J Med Chem; 2003 Mar; 46(7):1081-111. PubMed ID: 12646017
[No Abstract] [Full Text] [Related]
33. Effect of HMR 3339, a novel selective estrogen receptor modulator, on C-reactive protein levels in healthy postmenopausal women.
Vogelvang TE; Mijatovic V; Kenemans P; Schalkwijk CG; van der Mooren MJ
Am J Cardiol; 2004 Nov; 94(9):1205-8. PubMed ID: 15518626
[TBL] [Abstract][Full Text] [Related]
34. Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women.
Vogelvang TE; Leurs JR; van der Mooren MJ; Mijatovic V; Hendriks DF; Neele SJ; Netelenbos JC; Kenemans P
Menopause; 2004; 11(1):110-5. PubMed ID: 14716191
[TBL] [Abstract][Full Text] [Related]
35. Hormone alternative doesn't worsen vasomotor symptoms or impact urinary incontinence in post-menopausal women.
Rollins G
Rep Med Guidel Outcomes Res; 2004 Mar; 15(5):7-9. PubMed ID: 15025087
[No Abstract] [Full Text] [Related]
36. The controversy over estrogen replacement therapy: an update on clinical trials.
Gnatuk CL
Curr Womens Health Rep; 2002 Apr; 2(2):89-94. PubMed ID: 12116607
[TBL] [Abstract][Full Text] [Related]
37. [Hormonal replacement therapy and selective estrogen receptor modulators in prevention of cardiovascular disease].
Kozakiewicz K; Wycisk A
Wiad Lek; 2006; 59(5-6):377-82. PubMed ID: 17017486
[TBL] [Abstract][Full Text] [Related]
38. Effects of different postmenopausal hormone therapy regimens on cerebral blood flow and cognitive functions.
Guvenal T; Durna A; Erden O; Guvenal F; Cetin M; Cetin A
Adv Ther; 2009 Aug; 26(8):805-11. PubMed ID: 19672567
[TBL] [Abstract][Full Text] [Related]
39. Selective estrogen receptor modulators: a new category of compounds to extend postmenopausal women's health.
Goldstein SR
Int J Fertil Womens Med; 1999; 44(5):221-6. PubMed ID: 10569450
[TBL] [Abstract][Full Text] [Related]
40. [Selective estrogen-receptor modulators (SERM's) in postmenopausal women].
Hart W; Netelenbos JC
Ned Tijdschr Geneeskd; 1999 Aug; 143(35):1771-6. PubMed ID: 10494328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
